Exclusive Life Science Feature
Takeda's
Approach To Becoming
A Global Player In The
Vaccine Market
By Rob Wright, chief editor
I
n 2008 Takeda Pharmaceuticals took aim at becoming a global pharmaceutical company by making a
number of strategic moves, such as the dissolution
of the 23-year, 50/50 joint venture with Abbott, known
as TAP Pharmaceuticals, and acquiring Millennium
Pharmaceuticals (2008) and Nycomed. These changes
strengthened Takeda's position in two of the largest
pharmaceutical markets outside of Japan (U.S. and EU),
placing it on the verge of being the first Japanese company to be listed among the 10 largest pharmaceutical
companies in the world. With 2012 net sales of $18.4 billion, Takeda ranks twelfth, up four spots from the previous year. What will get them to the next level?
August 2013
LifeScienceLeader.com
25